-+ 0.00%
-+ 0.00%
-+ 0.00%

Pfizer And BioNTech Gain CHMP Backing For LP.8.1 COVID-19 Vaccine Offering Enhanced Protection Against Evolving SARS-CoV-2 Sublineages

Benzinga·07/25/2025 06:42:16
Listen to the news
  • Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations
  • Upon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and older
  • To date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing data
  • Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission